It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...
BioMarin's new CEO had promised Wall Street there would be deals, and with Amicus, it has one the market likes.
The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.
With its vaccine schedule, “Denmark has made a values choice to accept preventable hospitalizations and illnesses that other ...
The Trump administration intends to make its most forceful attempt yet at restricting gender-affirming care for transgender ...
WASHINGTON — Brand drugmakers have agreed to donate bulk ingredients to a national stockpile as part of deals with the Trump ...
Two government officials told STAT that the White House has been involved in final decisions about the FDA's new priority ...
Nine drugmakers are set to unveil deals with the Trump administration to lower the prices of some of their drugs, marking the ...
The award is in response to an “unsolicited proposal,” according to documents in the Federal Register. The University of ...
BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...
The Trump administration has announced sweeping policies that, if enacted, could effectively end gender-affirming care for ...
The co-founder of SCIMaP looks at the year of NIH cuts — and what they say about the future of American research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback